<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Leuk Res Rep</journal-id><journal-id journal-id-type="iso-abbrev">Leuk Res Rep</journal-id><journal-title-group><journal-title>Leukemia Research Reports</journal-title></journal-title-group><issn pub-type="epub">2213-0489</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24596676</article-id><article-id pub-id-type="pmc">3939385</article-id><article-id pub-id-type="publisher-id">S2213-0489(13)00029-0</article-id><article-id pub-id-type="doi">10.1016/j.lrr.2013.12.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia<sup><xref ref-type="fn" rid="d32e417">&#x02606;</xref></sup><sup><xref ref-type="fn" rid="d32e422">&#x02606;&#x02606;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Delaunay</surname><given-names>Jacques</given-names></name><email>jacques.delaunay@chu-nantes.fr</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Mazur</surname><given-names>Grzegorz</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Minden</surname><given-names>Mark</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Wierzbowska</surname><given-names>Agnieszka</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Mark M.</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Berrak</surname><given-names>Erhan</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Kantarjian</surname><given-names>Hagop M.</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>University of Nantes, Nantes, France</aff><aff id="aff0010"><label>b</label>Wroclaw Medical University, Wroclaw, Poland</aff><aff id="aff0015"><label>c</label>Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada</aff><aff id="aff0020"><label>d</label>Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland</aff><aff id="aff0025"><label>e</label>Eisai Corporation, Woodcliff Lake, NJ, USA</aff><aff id="aff0030"><label>f</label>The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Correspondence to: Nantes University Hospital, CHU H&#x000f4;tel Dieu, Nantes Cedex 1, 44093 France. Tel.: +33 40083271; fax: +33 40083250. <email>jacques.delaunay@chu-nantes.fr</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>27</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>3</volume><issue>1</issue><fpage>17</fpage><lpage>20</lpage><history><date date-type="received"><day>28</day><month>5</month><year>2013</year></date><date date-type="rev-recd"><day>6</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>3</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 The Authors</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>In a phase III trial, older patients with acute myeloid leukemia (<italic>N</italic>=485) received decitabine or treatment choice (supportive care or cytarabine). This post hoc analysis examined whether baseline renal and hepatic function and white blood cell (WBC) counts predicted response.</p></sec><sec><title>Methods</title><p>Baseline WBCs and renal and liver function markers were tabulated for responders/nonresponders.</p></sec><sec><title>Results</title><p>Nonresponders had higher mean baseline creatinine (<italic>P</italic>=0.005). Creatinine data showed no significant between-group differences by treatment within responder category.</p></sec><sec><title>Conclusions</title><p>No relationship was found between baseline WBCs or hepatic function and response. Higher baseline creatinine in nonresponders may not be clinically relevant.</p></sec></abstract><kwd-group><title>Abbreviations</title><kwd>ALT, alanine aminotransferase</kwd><kwd>AML, acute myeloid leukemia</kwd><kwd>AST, aspartate aminotransferase</kwd><kwd>BUN, blood urea nitrogen</kwd><kwd>CR, complete response</kwd><kwd>CRi, complete response with incomplete blood count recovery</kwd><kwd>ECOG PS, Eastern Cooperative Oncology Group Performance Status</kwd><kwd>FAB, French&#x02013;American&#x02013;British classification</kwd><kwd>PR, partial remission</kwd><kwd>SC, supportive care</kwd><kwd>WBC, white blood cell</kwd></kwd-group><kwd-group><title>Keywords</title><kwd>Decitabine</kwd><kwd>Acute myeloid leukemia</kwd><kwd>Prognosis</kwd><kwd>Leukemia</kwd><kwd>Adult</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s0005"><label>1</label><title>Introduction</title><p>Acute myeloid leukemia (AML) is a common adult leukemia, with &#x02248;12,330 new cases reported annually in the United States <xref rid="bib1" ref-type="bibr">[1]</xref> and &#x02248;18,000 new cases reported annually in the European Union <xref rid="bib2" ref-type="bibr">[2]</xref>. While AML is more common in the elderly <xref rid="bib3" ref-type="bibr">[3]</xref>, treatments for these patients are limited, especially for patients with poor performance status and/or comorbidities. The US National Comprehensive Cancer Network <xref rid="bib3" ref-type="bibr">[3]</xref> and the European LeukemiaNet <xref rid="bib4" ref-type="bibr">[4]</xref> recently updated their AML treatment guidelines to include low-intensity cytarabine, 5-azacytidine, and decitabine as recommended therapies for these patients.</p><p>Decitabine, a hypomethylating agent, is indicated in the US for the treatment of de novo and secondary myelodysplastic syndrome of all French&#x02013;American&#x02013;British (FAB) subtypes and for intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups <xref rid="bib5" ref-type="bibr">[5]</xref>. In Europe, decitabine is used to treat adults aged &#x02265;65 years with newly diagnosed or secondary AML (according to World Health Organisation [WHO] classification) who are not eligible for initial treatment with standard chemotherapy <xref rid="bib6" ref-type="bibr">[6]</xref>.</p><p>A phase III trial was conducted in 485 patients aged &#x02265;65 years with newly diagnosed AML <xref rid="bib7" ref-type="bibr">[7]</xref>. Every 4 weeks, patients received decitabine 20&#x000a0;mg/m<sup>2</sup> (1-h intravenous infusion for 5 successive days) or patient's choice of treatment, with physician's advice, with either supportive care (SC) or cytarabine (20&#x000a0;mg/m<sup>2</sup> subcutaneous injection daily for 10 successive days) <xref rid="bib7" ref-type="bibr">[7]</xref>. This post hoc analysis of this patient population examined whether baseline renal and hepatic function and white blood cell (WBC) counts are associated with response to decitabine or treatment choice.</p></sec><sec sec-type="materials|methods" id="s0010"><label>2</label><title>Materials and methods</title><p>For patients with available data, baseline WBC count and markers of renal function (blood urea nitrogen [BUN], creatinine, and creatinine clearance) and of hepatic function (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin, and albumin) were compared for patients with and without a response to decitabine or treatment choice. Response was defined as morphologic complete remission (CR), CR with incomplete blood count recovery (CRi), or partial remission (PR), with morphologic CR defined per the International Working Group 2003 criteria <xref rid="bib7 bib8" ref-type="bibr">[7,8]</xref>. Comparisons between responders and nonresponders were made and <italic>P</italic> values calculated using a 2-sided <italic>t</italic> test assuming unequal group variances (significance level &#x0003c;0.05). Creatinine levels were also analyzed at baseline and day 1 of each cycle, stratified by response and treatment group, using a 2-sided <italic>t</italic> test assuming unequal group variances.</p><p>Baseline creatinine levels were analyzed using logistic regression analysis based on responders (CR+CRi+PR) vs nonresponders, Eastern Cooperative Oncology Group Performance Status (ECOG PS) &#x02265;2 vs 0&#x02013;1, and FAB subtype M4/M4eos/M5 vs others (excluding patients with missing FAB subtypes).</p></sec><sec sec-type="results" id="s0015"><label>3</label><title>Results</title><p>A total of 485 patients were randomized to either decitabine (<italic>n</italic>=242) or treatment choice (<italic>n</italic>=243) in the phase 3 trial <xref rid="bib7" ref-type="bibr">[7]</xref>. At baseline, the median age of patients was 73 years (range, 64&#x02013;89 years) in the decitabine group and 73 years (range, 64&#x02013;91 years) in the treatment choice group. In the decitabine and treatment choice groups, respectively, median time since AML diagnosis was 14 days (range, 3&#x02013;346) and 15 days (range, 0&#x02013;398), and 36% and 35% of patients had secondary AML. In the decitabine group, 44% of patients had more than 50% bone marrow blasts and median white blood cell count was 3.10 (0.3&#x02013;127.0) 10<sup>9</sup>/L. In the treatment choice group, 42% of patients had more than 50% bone marrow blasts and median white blood cell count was 3.69 (0.5&#x02013;80.9) 10<sup>9</sup>/L. In each group, 36% of patients had poor-risk cytogenetics <xref rid="bib7" ref-type="bibr">[7]</xref>.</p><p>Overall, 102 of 485 patients (21.2%) were responders (CR+CRi+PR), including 68 of 242 patients (28.1%) in the decitabine group and 34 of 243 patients (14.0%) in the treatment choice group.</p><p>Baseline WBC count and baseline measures of hepatic and renal function for responders and nonresponders are shown in <xref rid="t0005" ref-type="table">Table 1</xref>. No relationship was evident between responders to decitabine or treatment choice and baseline WBC counts, or between responders and baseline measures of hepatic function (ALT, AST, total bilirubin, and albumin). Regarding renal function (BUN, creatinine, creatinine clearance), nonresponders had a significantly higher mean baseline creatinine level compared with responders (86.78 vs 80.23&#x000a0;&#x003bc;mol/L, respectively; <italic>P</italic>=0.005), and correspondingly lower, although not significantly, creatinine clearance (68.35 vs 72.42&#x000a0;&#x003bc;mol/L, respectively; <italic>P</italic>=0.067). However, no significant difference between nonresponders and responders was noted in mean baseline BUN (6.97 vs 6.48&#x000a0;mmol/L, respectively; <italic>P</italic>=0.067) <xref rid="bib7" ref-type="bibr">[7]</xref>.</p><p>An analysis was also conducted on creatinine data for responders and nonresponders by treatment group (decitabine vs treatment choice). Mean baseline creatinine levels (&#x000b1; standard deviation) by treatment group were 78.81&#x000b1;15.78&#x000a0;&#x003bc;mol/L for decitabine responders (<italic>n</italic>=68) and 83.06&#x000b1;23.94&#x000a0;&#x003bc;mol/L for treatment choice responders (<italic>n</italic>=34). Corresponding levels for nonresponders were 85.78&#x000b1;26.99&#x000a0;&#x003bc;mol/L for decitabine (<italic>n</italic>=171) and 87.62&#x000b1;27.19&#x000a0;&#x003bc;mol/L for treatment choice (<italic>n</italic>=206). No significant differences were seen when treatment groups were compared within responder categories.</p><p>Changes in creatinine levels over time by response to decitabine or treatment choice (<xref rid="f0005" ref-type="fig">Fig. 1</xref>) showed no clear trends or differences in change from baseline in creatinine levels between responders and nonresponders by treatment group.</p><p>Logistic regression analysis showed that if baseline creatinine levels increased 1 unit, the odds of achieving a response were 0.988. Additionally, patients with &#x0201c;other&#x0201d; FAB classifications were less likely than patients with M4/M4E0/M5 to respond (odds ratio=0.807) to treatment, and patients with ECOG PS &#x02265;2 were less likely to respond than patients with ECOG PS 0&#x02013;1 (odds ratio=0.861). Compared with patients receiving SC, patients receiving decitabine were 3.144 times more likely to respond, and patients receiving cytarabine were 1.44 times more likely to respond.</p></sec><sec sec-type="discussion" id="s0020"><label>4</label><title>Discussion</title><p>This post hoc analysis of data from a large phase 3 trial in older patients with AML <xref rid="bib7" ref-type="bibr">[7]</xref> suggests that no relationship exists between baseline WBC count or hepatic function and response to treatment with decitabine or patient's treatment choice of either supportive care or cytarabine. In contrast, another study of older patients with AML reported that higher peripheral blood blast counts were associated with poorer response rates to decitabine <xref rid="bib9" ref-type="bibr">[9]</xref>. Regarding renal function, although baseline BUN and creatinine clearance had no effect on response to treatment with decitabine or treatment choice, higher mean creatinine levels in nonresponders across both treatment groups suggested a possible prognostic relationship. However, the clinical relevance of this result is questionable. Other explanations might be patient-related, e.g., comorbidities or poor physical condition, and patients who have AML with a high monocytic component may have increased creatinine at diagnosis <xref rid="bib10" ref-type="bibr">[10]</xref>. A logistic regression analysis of confounding factors and creatinine levels confirmed that patients receiving SC were less likely to respond as creatinine levels increased, as were patients with an ECOG PS &#x02265;2.</p><p>No notable differences were found in creatinine levels or in change from baseline between responders and nonresponders to decitabine or treatment choice in these older patients with AML, suggesting that renal function did not adversely affect response to decitabine. Further studies may clarify whether there is any relationship between creatinine levels in older patients with AML who do not respond to decitabine or to treatment choice of supportive care or cytarabine.</p></sec><sec id="s0025"><title>Role of the funding source</title><p>Eisai Inc. participated in/contributed to the original study design, analyzing the data, and interpretation of the data. Yuhan Li, MS, of Eisai Inc. provided statistical analyses of the data. Eisai Inc. also reviewed the manuscript and acknowledged the authors' decision to submit the manuscript for publication.</p></sec><sec id="s0030"><title>Author contributions</title><p><list list-type="simple"><list-item id="u0005"><p>Study design: HK</p></list-item><list-item id="u0010"><p>Study investigator: JD, HK, GM, MM, AW</p></list-item><list-item id="u0015"><p>Enrolled patients: JD, HK, GM, MM, AW</p></list-item><list-item id="u0020"><p>Collection and assembly of data: HK, GM, AW</p></list-item><list-item id="u0025"><p>Data analysis and interpretation: JD, HK, MJ, EB, GM, MM, AW</p></list-item><list-item id="u0030"><p>Manuscript preparation: JD, HK, MJ, EB</p></list-item><list-item id="u0035"><p>Manuscript review and revisions: All authors</p></list-item><list-item id="u0040"><p>Final approval of manuscript: All authors.</p></list-item></list></p></sec><sec id="s0035"><title>Conflict of interest statement</title><p>Jacques Delaunay has served as a consultant for Novartis and Genzyme. Grzegorz Mazur has no relevant conflicts of interest to disclose. Mark Minden has served as a consultant for Teva. Agnieszka Wierzbowska has no relevant conflicts of interest to disclose. Mark Jones and Erhan Berrak are employees of Eisai Inc. Hagop M. Kantarjian's institution has received research grants from Eisai Inc.</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sbref1"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A.</given-names></name><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Ward</surname><given-names>E.</given-names></name></person-group><article-title>Cancer statistics, 2010</article-title><source>CA Cancer J Clin</source><volume>60</volume><year>2010</year><fpage>277</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">20610543</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sbref2"><person-group person-group-type="author"><name><surname>Rodriguez-Abreu</surname><given-names>D.</given-names></name><name><surname>Bordoni</surname><given-names>A.</given-names></name><name><surname>Zucca</surname><given-names>E.</given-names></name></person-group><article-title>Epidemiology of hematological malignancies</article-title><source>Ann Oncol</source><volume>18</volume><issue>Suppl. 1</issue><year>2007</year><fpage>i3</fpage><lpage>i8</lpage><pub-id pub-id-type="pmid">17311819</pub-id></element-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="other" id="othref0005">National comprehensive cancer network. NCCN clinical practice guidelines in oncology: acute myeloid leukemia. v.1.2012. Fort Washington, PA: National Comprehensive Cancer Network; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/all.pdf" id="ir0005">&#x02329;www.nccn.org/professionals/physician_gls/pdf/all.pdf&#x0232a;</ext-link>. [accessed 26.11.12].</mixed-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sbref3"><person-group person-group-type="author"><name><surname>Dohner</surname><given-names>H.</given-names></name><name><surname>Estey</surname><given-names>E.H.</given-names></name><name><surname>Amadori</surname><given-names>S.</given-names></name><name><surname>Appelbaum</surname><given-names>F.R.</given-names></name><name><surname>Buchner</surname><given-names>T.</given-names></name><name><surname>Burnett</surname><given-names>A.K.</given-names></name></person-group><article-title>Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</article-title><source>Blood</source><volume>115</volume><year>2010</year><fpage>453</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">19880497</pub-id></element-citation></ref><ref id="bib5"><label>5</label><mixed-citation publication-type="other" id="othref0010">Dacogen [package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2010.</mixed-citation></ref><ref id="bib6"><label>6</label><mixed-citation publication-type="other" id="othref0015">Dacogen [Annex 1 summary of product characteristics]. London, United Kingdom: European Medicines Agency; February; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002221/human_med_001589.jsp&#x00026;mid=WC0b01ac058001d124" id="ir0010">&#x02329;www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002221/human_med_001589.jsp&#x00026;mid=WC0b01ac058001d124&#x0232a;</ext-link> [accessed 11.02.13].</mixed-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sbref4"><person-group person-group-type="author"><name><surname>Kantarjian</surname><given-names>H.M.</given-names></name><name><surname>Thomas</surname><given-names>X.G.</given-names></name><name><surname>Dmoszynska</surname><given-names>A.</given-names></name><name><surname>Wierzbowska</surname><given-names>A.</given-names></name><name><surname>Mazur</surname><given-names>G.</given-names></name><name><surname>Mayer</surname><given-names>J.</given-names></name></person-group><article-title>Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia</article-title><source>J Clin Oncol</source><volume>30</volume><year>2012</year><fpage>2670</fpage><lpage>2677</lpage><pub-id pub-id-type="pmid">22689805</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sbref5"><person-group person-group-type="author"><name><surname>Cheson</surname><given-names>B.D.</given-names></name><name><surname>Bennett</surname><given-names>J.M.</given-names></name><name><surname>Kopecky</surname><given-names>K.J.</given-names></name><name><surname>Buchner</surname><given-names>T.</given-names></name><name><surname>Willman</surname><given-names>C.L.</given-names></name><name><surname>Estey</surname><given-names>E.H.</given-names></name></person-group><article-title>Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia</article-title><source>J Clin Oncol</source><volume>21</volume><year>2003</year><fpage>4642</fpage><lpage>4649</lpage><pub-id pub-id-type="pmid">14673054</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sbref6"><person-group person-group-type="author"><name><surname>Cashen</surname><given-names>A.F.</given-names></name><name><surname>Schiller</surname><given-names>G.J.</given-names></name><name><surname>O'Donnell</surname><given-names>M.R.</given-names></name><name><surname>Dipersio</surname><given-names>JF. Multicenter</given-names></name></person-group><article-title>Phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia</article-title><source>J Clin Oncol</source><volume>28</volume><year>2010</year><fpage>556</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">20026803</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sbref7"><person-group person-group-type="author"><name><surname>Tobelem</surname><given-names>G.</given-names></name><name><surname>Jacquillat</surname><given-names>C.</given-names></name><name><surname>Chastang</surname><given-names>C.</given-names></name><name><surname>Auclerc</surname><given-names>M.F.</given-names></name><name><surname>Lechevallier</surname><given-names>T.</given-names></name><name><surname>Weil</surname><given-names>M.</given-names></name></person-group><article-title>Acute monoblastic leukemia: a clinical and biologic study of 74 cases</article-title><source>Blood</source><volume>55</volume><year>1980</year><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">6927957</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgments</title><p>The original study and this analysis were funded by <funding-source id="GS1">Eisai Inc, Woodcliff Lakes, NJ</funding-source>. Medical writing, editing, and graphics assistance was provided by Peloton Advantage, LLC, and was funded by <funding-source id="GS2">Eisai Inc</funding-source>. The authors thank Yvonne E. Yarker, PhD, CMPP, of Peloton Advantage for medical writing support and Yuhan Li, MS, of Eisai Inc. for statistical analyses provided during the development of this manuscript.</p></ack><fn-group><fn id="d32e417"><label>&#x02606;</label><p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.</p></fn><fn id="d32e422"><label>&#x02606;&#x02606;</label><p><bold>Clinicaltrials.gov identifier:</bold> NCT00260832.</p><p>These data were presented in part at the Annual Meeting of the American Society of Clinical Oncology, June 1&#x02013;5, 2012, in Chicago, IL (abstract 6632).</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Fig. 1</label><caption><p>Changes (mean&#x000b1;SD) in creatinine levels over time by response to either decitabine or treatment choice.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Relationship between response to decitabine or treatment choice and baseline white blood cell count, hepatic function (ALT, AST, bilirubin, and albumin), and renal function (BUN and creatinine) in older patients with acute myeloid leukemia.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Parameter</bold></th><th><bold>Nonresponder to Decitabine or Treatment Choice</bold><xref rid="tbl1fna" ref-type="table-fn">a</xref></th><th><bold>Responder to Decitabine or Treatment Choice</bold><xref rid="tbl1fna" ref-type="table-fn">a</xref><bold>(CR+CRi+PR)</bold></th><th><italic><bold>P</bold></italic><bold>value</bold><xref rid="tbl1fnb" ref-type="table-fn">b</xref></th></tr></thead><tbody><tr><td>WBC (10<sup>9</sup>/L)</td><td/><td/><td/></tr><tr><td>&#x000a0;&#x000a0;<italic>N</italic></td><td>372</td><td>101</td><td/></tr><tr><td>&#x000a0;&#x000a0;Mean (SD)</td><td>9.25 (13.98)</td><td>7.02 (12.25)</td><td align="char">0.117</td></tr><tr><td>&#x000a0;&#x000a0;Median (range)</td><td>4 (0.3&#x02013;127)</td><td>3 (0.4&#x02013;96)</td><td/></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td>ALT (U/L)</td><td/><td/><td/></tr><tr><td>&#x000a0;&#x000a0;<italic>N</italic></td><td>372</td><td>100</td><td/></tr><tr><td>&#x000a0;&#x000a0;Mean (SD)</td><td>25.32 (35.53)</td><td>20.79 (14.53)</td><td align="char">0.054</td></tr><tr><td>&#x000a0;&#x000a0;Median (range)</td><td>18 (5&#x02013;614)</td><td>17 (6&#x02013;103)</td><td/></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td>AST (U/L)</td><td/><td/><td/></tr><tr><td>&#x000a0;&#x000a0;<italic>N</italic></td><td>371</td><td>101</td><td/></tr><tr><td>&#x000a0;&#x000a0;Mean (SD)</td><td>23.82 (15.93)</td><td>21.74 (9.84)</td><td align="char">0.106</td></tr><tr><td>&#x000a0;&#x000a0;Median (range)</td><td>20 (5&#x02013;203)</td><td>18 (9&#x02013;65)</td><td/></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td>Total bilirubin (&#x003bc;mol/L)</td><td/><td/><td/></tr><tr><td>&#x000a0;&#x000a0;<italic>N</italic></td><td>376</td><td>100</td><td/></tr><tr><td>&#x000a0;&#x000a0;Mean (SD)</td><td>10.00 (5.06)</td><td>10.8 (5.20)</td><td align="char">0.174</td></tr><tr><td>&#x000a0;&#x000a0;Median (range)</td><td>9 (3&#x02013;33)</td><td>10 (3&#x02013;29)</td><td/></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td>Albumin (g/L)</td><td/><td/><td/></tr><tr><td>&#x000a0;&#x000a0;<italic>N</italic></td><td>377</td><td>102</td><td/></tr><tr><td>&#x000a0;&#x000a0;Mean (SD)</td><td>34.18 (5.47)</td><td>35.07 (5.34)</td><td align="char">0.140</td></tr><tr><td>&#x000a0;&#x000a0;Median (range)</td><td>35 (19&#x02013;48)</td><td>36 (16&#x02013;44)</td><td/></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td>BUN (mmol/L)</td><td/><td/><td/></tr><tr><td>&#x000a0;&#x000a0;<italic>N</italic></td><td>377</td><td>102</td><td/></tr><tr><td>&#x000a0;&#x000a0;Mean (SD)</td><td>6.97 (2.65)</td><td>6.48 (2.27)</td><td align="char">0.067</td></tr><tr><td>&#x000a0;&#x000a0;Median (range)</td><td>6 (1&#x02013;23)</td><td>6 (3&#x02013;20)</td><td/></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td>Creatinine (&#x003bc;mol/L)</td><td/><td/><td/></tr><tr><td>&#x000a0;&#x000a0;<italic>N</italic></td><td>377</td><td>102</td><td/></tr><tr><td>&#x000a0;&#x000a0;Mean (SD)</td><td>86.78 (27.08)</td><td>80.23 (18.88)</td><td align="char">0.005</td></tr><tr><td>&#x000a0;&#x000a0;Median (range)</td><td>81 (38&#x02013;254)</td><td>78 (44&#x02013;169)</td><td/></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td>CrCL (mL/min)<xref rid="tbl1fnc" ref-type="table-fn">c</xref></td><td/><td/><td/></tr><tr><td>&#x000a0;&#x000a0;<italic>N</italic></td><td>377</td><td>102</td><td/></tr><tr><td>&#x000a0;&#x000a0;Mean (SD)</td><td>68.35 (19.32)</td><td>72.42 (19.83)</td><td align="char">0.067</td></tr><tr><td>&#x000a0;&#x000a0;Median (range)</td><td>67 (23&#x02013;138)</td><td>67 (33&#x02013;133)</td><td/></tr></tbody></table><table-wrap-foot><fn><p>ALT, alanine aminotransferase; AML, acute myeloid leukemia; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CR, complete remission; CRi, CR with incomplete blood count recovery; CrCL, creatinine clearance; PR, partial remission; SD, standard deviation; WBC, white blood cell.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p>Either supportive care or cytarabine.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p>2-sided <italic>t</italic> test assuming unequal group variances.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnc"><label>c</label><p>Calculated using the Cockcroft&#x02013;Gault method.</p></fn></table-wrap-foot></table-wrap></floats-group></article>